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Abstract
Objectives: Contradictory	 results	 have	 been	 reported	 regarding	 the	 association	
between	polycystic	ovary	syndrome	(PCOS)	and	cardiovascular	disease	(CVD).	We	
assessed	 the	 cardiometabolic	 phenotype	 and	 prevalence	 of	 CVD	 in	 middle‐aged	
women	with	PCOS,	compared	with	age‐matched	controls	from	the	general	popula‐
tion,	and	estimated	10‐year	CVD	risk	and	cardiovascular	health	score.
Design: A	cross‐sectional	study.
Participants: 200	women	aged	>45	with	PCOS,	and	200	age‐matched	controls.
Measurements: Anthropometrics,	 insulin,	 lipid	 levels,	 prevalence	 of	metabolic	 syn‐
drome	and	type	II	diabetes.	Ten‐year	Framingham	risk	score	and	the	cardiovascular	
health	score	were	calculated,	and	carotid	intima‐media	thickness	(cIMT)	was	measured.
Results: Mean	age	was	50.5	years	(SD	=	5.5)	 in	women	with	PCOS	and	51.0	years	
(SD	=	5.2)	 in	controls.	 Increased	waist	circumference,	body	mass	 index	and	hyper‐
tension	were	more	often	observed	in	women	with	PCOS	(P	<	.001).	In	women	with	
PCOS,	the	prevalence	of	type	II	diabetes	and	metabolic	syndrome	was	not	signifi‐
cantly	increased	and	lipid	levels	were	not	different	from	controls.	cIMT	was	lower	in	
women	with	PCOS	(P	<	.001).	Calculated	cardiovascular	health	and	10‐year	CVD	risk	
were	similar	in	women	with	PCOS	and	controls.
Conclusions: Middle‐aged	women	with	PCOS	exhibit	only	a	moderately	unfavour‐
able	cardiometabolic	profile	compared	to	age‐matched	controls,	even	though	they	
present	with	an	increased	BMI	and	waist	circumference.	Furthermore,	we	found	no	
evidence	for	increased	(10‐year)	CVD	risk	or	more	severe	atherosclerosis	compared	
with	 controls	 from	 the	 general	 population.	 Long‐term	 follow‐up	 of	 women	 with	
PCOS	is	necessary	to	provide	a	definitive	answer	concerning	long‐term	risk	for	CVD.
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution‐NonCommercial	License,	which	permits	use,	distribution	and	reproduction	
in	any	medium,	provided	the	original	work	is	properly	cited	and	is	not	used	for	commercial	purposes. 
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1  | INTRODUC TION
Cardiovascular	disease	(CVD)	is	the	leading	cause	of	morbidity	and	
mortality	 in	 women	 worldwide.1	 Risk	 factors	 for	 CVD	 are	 more	
prevalent	and	tend	to	cluster	in	women	with	polycystic	ovary	syn‐
drome	(PCOS).2,3	This	syndrome	represents	the	most	common	en‐
docrine	disorder	in	women	of	reproductive	age,	with	a	prevalence	of	
up	to	15%.4	PCOS	has	been	associated	with	cardiometabolic	abnor‐
malities	such	as	obesity,	dyslipidemia,	type	II	diabetes,	hypertension	
and	 the	metabolic	 syndrome,	which	 increase	 the	 risk	 for	 CVD.5,6 
PCOS	is	a	syndrome	characterized	by	ovulatory	dysfunction,	hyper‐
androgenism	and	polycystic	ovarian	morphology.7	The	phenotype	
of	PCOS	is	modified	by	body	mass	index	(BMI)	and	ethnicity,	gener‐
ally	becomes	milder	with	increasing	age,	and	disappears	largely	after	
menopause.8‐10	The	cardiometabolic	abnormalities	associated	with	
PCOS	can,	however,	persist	beyond	the	onset	of	menopause.5,8,11
In	 the	past,	 it	was	assumed	that	women	with	PCOS	would	be	
more	prone	to	develop	CVD	later	in	life.12	The	only	available	long‐
term	follow‐up	study	in	women	with	PCOS	did,	however,	not	reveal	
an	 increased	 risk	 for	 CVD.6	 More	 recent	 studies	 in	 postmeno‐
pausal	women	with	features	of	PCOS	seem	to	reinforce	these	find‐
ings.11,13	At	the	same	time,	others	suggest	an	increased	incidence	
of	CVD	in	women	with	PCOS	already	at	an	early	age.14‐16	Whether	
or	not	women	with	PCOS	are	at	increased	risk	to	develop	CVD	still	
remains	uncertain.	Long	before	the	onset	of	cardiovascular	events,	
atherosclerosis	 can	 be	 detected.	 Carotid	 intima‐media	 thickness	
(cIMT)	 is	 a	marker	of	 subclinical	 atherosclerosis	 and	 can	be	used	
to	predict	future	cardiovascular	events.17	In	women	with	PCOS,	an	
increased	cIMT	has	been	described,	which	suggests	an	 increased	
risk	for	accelerated	atherosclerosis	compared	to	the	general	pop‐
ulation.18	It	remains	to	be	determined	to	what	extent	these	surro‐
gate	markers	translate	into	real	cardiovascular	events	later	in	life.19
In	addition	to	markers	used	to	detect	 (early)	signs	of	CVD,	mod‐
els	 have	been	developed	 to	 estimate	 cardiovascular	 health	 and	 car‐
diovascular	disease	risk.20,21	The	Framingham	study	has	provided	an	
algorithm	to	predict	the	risk	for	future	CVD,	based	on	factors	such	as	
smoking,	BMI	and	cholesterol	levels.21	At	the	same	time,	the	American	
Heart	Association	has	identified	factors	and	behaviours,	which	improve	
cardiovascular	health	and	reduce	death	from	CVD.	The	simultaneous	
presence	of	ideal	health	factors	and	behaviours	in	an	individual	is	as‐
sociated	with	 longevity	and	healthy	ageing.20,21	Not	much	 is	known	
about	the	performance	of	women	with	PCOS	in	these	models.
The	aim	of	the	current	study	was	to	assess	the	cardiometabolic	
phenotype	 and	 prevalence	 of	 CVD	 in	 middle‐aged	 women	 previ‐
ously	diagnosed	with	PCOS,	compared	with	age‐matched	controls	
from	the	general	population.	We	compared	the	cardiovascular	pro‐
file	and	assessed	the	presence	of	subclinical	atherosclerosis,	by	mea‐
suring	cIMT.	 In	addition,	we	assessed	differences	 in	 the	estimated	
cardiovascular	 health	 score	 and	 10‐year	 CVD	 risk	 between	 the	
aforementioned	populations.
2  | METHODS
2.1 | Patients
Women	aged	≥40	years	who	were	previously	diagnosed	with	PCOS	
in	one	of	the	three	participating	university	hospitals	were	eligible	for	
inclusion.	All	patients	had	in	the	past	underwent	a	standardized	ex‐
amination,	involving	a	questionnaire,	anthropometric	measurements,	
hormonal	 evaluation	 and	 a	 transvaginal	 ultrasonography	 to	 assess	
ovarian	volume	and	follicle	count.	This	protocol	has	been	described	in	
detail	elsewhere	22	Diagnosis	of	PCOS	was	based	on	the	Rotterdam	
criteria	 and	established	during	 the	 reproductive	years.10	According	
to	these	criteria,	PCOS	is	diagnosed	when	either	two	or	three	of	the	
key	 features	are	present:	ovulatory	dysfunction,	polycystic	ovarian	
morphology	 and	 clinical	 and/or	biochemical	 hyperandrogenism.7	 In	
total,	around	850	women	had	previously	been	diagnosed	and	pheno‐
typed	by	this	standardized	screening	and	by	now	reached	the	age	of	
40.	Women	with	a	poor	ability	of	speaking	or	understanding	of	Dutch	
or	English	language	or	who	were	currently	pregnant	were	excluded.	
All	other	women	with	PCOS	aged	>40	were	invited	to	participate	in	
the	current	study.	Women	visiting	the	outpatient	clinic	underwent	an	
extensive	endocrine	and	cardiovascular	assessment,	which	included	
general	medical,	obstetric	and	family	history,	education	level,	smok‐
ing	status	and	anthropometric	measurements.	Visualization	of	both	
carotid	arteries	was	done	using	ultrasound.	This	study	was	approved	
by	 the	 institutional	 review	board	of	 the	University	Medical	Center	
Utrecht,	University	 of	Utrecht	 and	 registered	 at	www.clini	caltr	ials.
gov,	 registration	number	NCT02616510.	Written	 informed	consent	
was	obtained	from	all	participants.
2.2 | Controls
The	 control	 group	 was	 derived	 from	 the	 Rotterdam	 Study,	 a	
prospective	 population‐based	 cohort	 study	 focusing	 on	 health	
and	 diseases	 in	 the	 elderly.	 We	 selected	 200	 women	 included	
in	 the	 third	 cohort	of	 the	Rotterdam	Study.	The	 third	 cohort	 in‐
cludes	 inhabitants	 of	 the	 municipality	 of	 Ommoord,	 Rotterdam	
aged	 >45	 years,	 and	 was	 recruited	 between	 2006	 and	 2008.	
Participants	 are	 examined	 extensively	 at	 the	 research	 centre	
every	3‐5	years.	The	rationale	and	design	of	this	study	have	been	
described	 in	 detail	 elsewhere.23	 All	 participants	 provided	 writ‐
ten	 informed	 consent	 to	 participate	 in	 the	 study	 and	 to	 obtain	
information	 from	their	 treating	physicians.	The	Rotterdam	Study	
has	 been	 approved	 by	 the	 medical	 ethics	 committee	 according	
to	 the	 Population	 Screening	Act:	 Rotterdam	 Study,	 executed	 by	
91616079;	the	Netherlands	Organization	for	
Scientific	Research,	Grant/Award	Number:	
VENI	91616079
K E Y W O R D S
cardiovascular	disease	(7),	polycystic	ovary	syndrome
     |  3MEUN Et al.
the	Ministry	 of	Health,	Welfare	 and	 Sports	 of	 the	Netherlands.	
National	trial	registry	number	NTR6831.
2.3 | Endocrine and cardiovascular assessment of 
women with PCOS and controls
On	 the	 day	 of	 the	 assessment,	 fasting	 blood	 samples	 were	 col‐
lected	 and	 assessed.2,24	We	measured	 cholesterols,	 high‐density	
lipoprotein	 (HDL),	 low‐density	 lipoprotein	 (LDL)	 and	 triglyceride	
serum	 levels.	 Furthermore,	 insulin	 and	 glucose	 levels,	 aspartate	
transaminasel	 (ASAT)	 and	 alanine	 transaminase	 (ALAT),	 andro‐
gens,	 gonadotropins,	 sex	 hormone‐binding	 globulin	 (SHBG)	 and	
oestradiol	 (E2)	 levels	 were	 determined.	 Brain	 natriuretic	 peptide	
(NT‐proBNP),	 a	marker	 for	heart	 failure,	was	also	measured.	The	
free	androgen	index	was	calculated	as	(Testosterone/SHBG)*100.	
Waist	 to	hip	 ratio	was	 calculated	as	waist	 circumference/hip	 cir‐
cumference.	 Blood	 pressure	 was	 measured	 once	 in	 cases	 and	
twice	 in	controls,	 in	sitting	position	after	at	 least	 five	minutes	of	
rest	 with	 a	 random‐zero	 sphygmomanometer.	 Insulin	 resistance	
was	assessed	with	 the	homoeostasis	model	 assessment	 (HOMA‐
IR).	 Insulin	was	converted	 to	mU/L,	and	next,	 the	HOMA‐IR	was	
calculated	as:	fasting	serum	insulin	(mU/L)	x	fasting	plasma	glucose	
(mmol/L)	 /22.5.	 Diabetes	 was	 defined	 as	 a	 fasting	 glucose	 level	
of	≥	7.0	mmol/L,	use	of	anti‐diabetic	medication	or	self‐reported	di‐
agnosis.	Hypertension	was	defined	as	systolic	blood	pressure	(SBP)	
>139	mm	Hg	or	diastolic	blood	pressure	(DBP)	>89	mm	Hg	or	use	of	
antihypertensive	medication.	The	National	Cholesterol	Education	
Program	(NCEP)	definition	was	used	to	determine	the	presence	of	
the	metabolic	syndrome.25	According	to	this	definition,	metabolic	
syndrome	 is	 present	when	 ≥3	 of	 the	 following	 features	 are	 pre‐
sent:	waist	circumference	≥88	cm,	 fasting	glucose	≥	6.1	mmol/L,	
blood	 pressure	 >129/84	 mm	 Hg,	 high‐density	 lipoprotein	 (HDL)	
<1.3	mmol/L	and	triglycerides	(TG)	≥	1.7	mmol/L.	Vitamin	D	defi‐
ciency	was	defined	as	a	25‐OH‐D	serum	of	<50	nmol/L.
2.4 | Carotid intima‐media thickness for women 
with PCOS and controls
We	used	cIMT	to	assess	subclinical	atherosclerosis	 in	middle‐aged	
women	 with	 PCOS	 and	 age‐matched	 controls	 from	 the	 general	
population.	 cIMT	was	defined	as	 the	distance	between	 the	 lumen	
intima	and	the	media‐adventitia	and	measured	three	times	at	both	
sides	over	1	centimetre	 length	and	at	 least	0.5	centimetres	proxi‐
mal	of	the	bifurcation	of	the	common	carotid	artery,	or	at	the	begin‐
ning	of	the	dilatation	of	the	distal	common	carotid	artery	across	a	
length	of	1	centimetre.26‐28	The	mean	of	 the	right	and	 left	carotid	
arteries	was	used	for	analysis.	Ultrasound	measurements	were	per‐
formed	by	trained	professionals	at	 the	respective	research	centre.	
Multiple	devices	were	used	for	ultrasound	measurements.	In	women	
with	PCOS,	the	Panasonic	CardioHealthStation	(Yokohoma,	Japan),	
Esaote	MyLabTMOne	and	 the	ToshibaAplioArtida	Medical	System	
were	used.	Measurements	with	the	various	machines	yielded	similar	
results	across	the	different	research	centres	(Table	S1).	In	controls,	
the	ATL	UltraMark	IV	(Advanced	Technology	Laboratories,	Bothell)	
was	used.
2.5 | Other measurements
Women	with	PCOS	with	FSH	serum	levels	of	>40	(U/L)	in	combina‐
tion	with	an	amenorrhoea	were	labelled	as	postmenopausal.	In	con‐
trols,	 postmenopausal	 status	 was	 self‐reported	 via	 questionnaire.	
Information	on	prevalent	CVD	(stroke,	myocardial	infarction	and/or	
coronary	heart	disease)	was	self‐reported	or	obtained	through	gen‐
eral	practitioners	or	hospital	discharge	reports.	Smoking	status	was	
labelled	as	ever	or	never	smoker.	Former	smokers	and	current	smok‐
ers	were	grouped	as	‘ever	smokers’	as	it	was	not	known	how	long	ago	
women	had	stopped	smoking.	Ethnicity	was	self‐reported.
The	10‐year	CVD	risk	was	calculated	according	to	the	Framingham	
Risk	Score	(FRS),	and	based	on	age,	SBP,	HDL	and	total	cholesterol,	
smoking	and	the	presence	of	type	II	diabetes.21	Low	risk	was	defined	
as	a	10‐year	CVD	risk	<10%,	10%‐20%	as	intermediate	10‐year	CVD	
risk,	and	>20%	was	marked	as	high	10‐year	CVD	risk	CVD.	Next,	we	
calculated	the	CHS	 in	women	with	PCOS	and	controls.20	The	CHS	
was	introduced	by	the	American	Heart	Association	and	encompasses	
health	factors	(cholesterol	and	glucose	serum	levels,	blood	pressure	
and	BMI)	and	behavioural	factors	(smoking,	dietary	intake	and	phys‐
ical	activity).	Information	on	5	out	of	the	7	factors	(cholesterol,	glu‐
cose,	blood	pressure,	smoking	status	and	BMI)	was	available	in	our	
study	population.	We	did	not	have	information	on	dietary	intake	and	
physical	activity.	However,	measures	of	these	parameters	have	been	
marked	to	be	prone	to	sampling	variability	and	misclassification.29,30 
Therefore,	we	calculated	a	composite	CHS	based	on	the	5	available	
parameters	and	assessed	the	mean	CHS	and	performance	of	cases	
and	controls	on	each	of	the	health	metrics.
2.6 | Statistical analysis
For	each	case,	a	control	was	age‐matched	1:1,	from	the	Rotterdam	
study	 cohort,	 using	 propensity	 score	 matching	 (PSM)	 greedy	 ap‐
proach.	PSM	was	based	on	a	logistic	regression	model	that	includes	
PCOS	vs	no	PCOS	as	a	dichotomous	outcome	and	age	as	the	only	
covariate	under	study.	Hosmer‐Lemeshow	test	was	used	to	evalu‐
ate	goodness‐or‐fit	of	the	models.	Transformation	of	age	was	used	
based	 on	 lowess	 graph	 in	 order	 to	 choose	 the	 best	 fitting	model.	
Standardized	differences	and	plots	of	propensity	scores	distribution	
between	PCOS	and	control	group,	before	and	after	matching	proce‐
dure,	were	made	to	evaluate	the	balance	achieved.
All	 statistical	 analysis	were	performed	with	 IBM	SPSS	 statistics	
version	24	 (IBM	Corp.)	and	STATA	version	14.2	 (Station	College).	A	
two‐sided	P	 <	 .05	 denoted	 statistical	 significance.	Baseline	 charac‐
teristics	were	presented	as	mean	(standard	deviation	[SD])	or	median	
(interquartile	 range	 [IQR])	 for	 continuous	 variables	 and	 as	 propor‐
tions	 (%)	 for	 dichotomous	 variables.	 Continuous	 variables	 with	 a	
normal	distribution	were	compared	with	the	student	t	test	and	with	
Mann‐Whitney	U	 for	 nonnormally	 distributed	 variables.	Chi‐square	
test	or	Fisher's	exact	test	were	used	for	categorical	variables.	Linear	
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regression	was	used	to	assess	cIMT.	cIMT	was	log	transformed	to	ob‐
tain	a	normal	distribution.	Results	were	expressed	as	regression	co‐
efficients	(β)	and	corresponding	95%	confidence	intervals	(95%CI).	To	
eliminate	 the	 effect	 of	 possible	 confounders,	we	 adjusted	 for	BMI,	
smoking	 status,	 education	 level,	 research	 centre	 and	 menopausal	
status.
Finally,	using	the	propensity	score	matching	(greedy	approach),	
we	also	matched	cases	and	controls	on	both	age	and	BMI	and	re‐
peated	 all	 the	 analyses	 to	 examine	 the	 effect	 of	 BMI	 on	 the	 car‐
diometabolic	profile	of	women	with	PCOS.
3  | RESULTS
3.1 | General and cardiometabolic characteristics
In	 this	 cross‐sectional	 study,	we	compared	200	women	diagnosed	
with	PCOS	with	200	age‐matched	controls	from	the	general	popula‐
tion.	The	baseline	characteristics	of	the	total	study	population	are	
presented	in	Table	1.	The	mean	age	was	similar	in	women	with	PCOS	
(50.5	years,	SD	=	5.5)	and	controls	 (51.0	years,	SD	=	5.2).	Women	
with	PCOS	had	experienced	menarche	at	a	later	age	(13.7,	SD	=	2.6	
vs	12.8,	SD	=	1.6	[P	<	.001])	and	had	more	often	experienced	cycle	
irregularities	 in	the	past	 (69.8%	vs	12.5%	[P	<	 .001]).	Compared	to	
women	with	PCOS,	a	much	 larger	proportion	of	the	control	popu‐
lation	 was	 already	 postmenopausal	 (40.5%	 vs	 12.6%	 [P	 <	 .001]).	
Women	 with	 PCOS	 were	 less	 often	 smokers	 (41.5%	 vs	 64.8%	
[P	<	 .001])	and	had	more	often	attended	higher	general	education	
or	university	 (P	<	 .001).	The	 free	androgen	 index	was	significantly	
higher	 in	 women	with	 PCOS	 (1.9	 IQR	 1.2‐2.9	 vs	 1.2,	 IQR	 0.8‐1.7	
[P	<	.001]),	as	well	as	serum	levels	of	E2	 (P	=	.028),	whereas	SHBG	
levels	were	significantly	lower	(P	<	.001).
We	 observed	 a	 higher	 BMI	 (28.4,	 IQR	 23.8‐32.9	 vs	 26.3,	 IQR	
23.7‐29.8	[P	=	.015]),	higher	SBP	(130.0,	IQR	120.0‐140.0	vs	122.0,	
IQR	112.0‐136.0	[P	=	.003])	and	increased	waist	circumference	(93.0,	
IQR	 84.5‐107.0	 vs	 85.9,	 IQR	 79.5‐94.6	 [P	 <	 .001])	 in	women	with	
PCOS.	Moreover,	the	prevalence	of	hypertension	(48.2%	vs	26.5%	
[P	 <	 .001])	 was	 increased	 and	 we	 observed	 higher	 glucose	 levels	
(5.3,	IQR	5.0‐5.7	vs	5.1,	IQR	4.8‐5.5	[P	=	.019]).	No	differences	were	
found	in	serum	lipid	levels,	NT‐pro‐BNP	and	vitamin	D	levels,	prev‐
alence	of	cardiovascular	disease	or	type	II	diabetes.	The	prevalence	
of	the	metabolic	syndrome	was	higher	in	women	with	PCOS,	but	this	
result	did	not	reach	statistical	significance.	The	HOMA	assessment	
of	insulin	resistance	yielded	similar	results	(P	=	.647).	When	we	re‐
peated	the	analyses	in	an	age	and	BMI	matched	control	population	
of	171	women,	the	analyses	yielded	similar	results	(data	not	shown).
3.2 | Carotid intima‐media thickness
We	 observed	 a	 lower	mean	 cIMT	 (um)	 in	 women	 diagnosed	with	
PCOS	compared	to	age‐matched	controls	(612.8,	SD	=	93.6	vs	721.7,	
SD	=	118.4	[P	<	.001]).	The	latter	was	consistent	across	all	participat‐
ing	university	hospitals	(Table	S1).	In	a	linear	regression	model	after	
adjusting	 for	 BMI,	 smoking,	 SBP,	 education,	 measurement	 centre	
and	menopausal	status,	we	found	that	PCOS	was	associated	with	a	
lower	cIMT	β	(95%CI)	−0.212	(−0.283‐0.142,	P	<	.001).
3.3 | Ten‐year cardiovascular disease risk and the 
cardiovascular health score
The	median	10‐year	CVD	risk	was	5.79%	in	women	with	PCOS	and	
7.38%	in	controls	(P	=	.214).	Next,	we	categorized	women	into	low	
(<10%),	intermediate	(10%‐20%)	and	high	(>20%)	risk	for	a	cardiovas‐
cular	event	in	the	subsequent	10	years.	We	observed	no	significant	
differences	in	the	proportion	of	women	with	PCOS	and	controls	in	
each	risk	category	(P	=	.388,	Figure	1).
The	composite	cardiovascular	health	score	was	calculated	in	all	
patients	and	controls	with	available	 information	on	all	health	met‐
rics.	We	used	information	on	BMI,	blood	pressure,	glucose	and	cho‐
lesterol	serum	level	and	smoking	status.	We	were	able	to	calculate	
the	CHS	in	158	cases	and	199	controls.	The	mean	(SD)	CHS	in	PCOS	
women	was	5.69	(2.18)	and	5.71	(1.99)	in	controls	(P	=	.915).	The	per‐
formance	of	women	with	PCOS	and	controls	on	each	of	the	separate	
cardiovascular	health	metrics	are	presented	in	Figure	2.
4  | DISCUSSION
In	 this	 large	 cross‐sectional	 study	 in	 women	 with	 PCOS	 around	
the	age	of	50,	we	observed	that	women	with	PCOS	exhibit	only	a	
moderately	unfavourable	cardiometabolic	profile	compared	to	age‐
matched	controls,	despite	a	higher	BMI	and	larger	waist	circumfer‐
ence.	 The	prevalence	of	major	 risk	 factors	 for	CVD	or	CVD	 itself	
was	not	increased,	and	we	found	no	evidence	for	more	severe	ath‐
erosclerosis	in	women	suffering	from	PCOS.	Finally,	the	aggregated	
measure	 of	 10‐year	 CVD	 risk	 and	 overall	 performance	 on	 cardio‐
vascular	health	metrics	 in	women	with	PCOS	were	 similar	 to	age‐
matched	controls	from	the	general	population.
PCOS	is	associated	with	cardiometabolic	disturbances,	which	can	
persist	throughout	life.5,11	Indeed,	we	observed	that	compared	with	
age‐matched	controls,	waist	circumference,	BMI,	SBP	and	androgen	
levels	were	all	significantly	higher	and	the	prevalence	of	hyperten‐
sion	was	nearly	50%.	At	the	same	time,	we	observed	no	differences	
in	 lipid	 levels	 of	women	with	 PCOS	 and	 age‐matched	 controls.	 In	
addition,	neither	HOMA‐assessed	 insulin	 resistance,	nor	 the	prev‐
alence	of	type	II	diabetes,	metabolic	syndrome	or	CVD	was	signifi‐
cantly	increased	at	the	age	of	50,	despite	of	a	higher	BMI	and	blood	
pressure	 in	 women	 with	 PCOS.	 Atherosclerosis	 can	 be	 detected	
with	 cIMT	and	used	as	 a	predictor	 for	 future	CVD.	 In	 the	 current	
study,	we	measured	a	lower	cIMT	in	women	with	PCOS.	Variability	in	
measuring	techniques	and	devices	may	have	influenced	our	results,	
baring	reason	for	caution.	However,	this	finding	indicates	that	ath‐
erosclerosis	is	not	more	advanced	in	women	with	PCOS.17,31	In	line	
with	this,	both	the	estimated	Framingham	10‐year	CVD	risk	and	the	
cardiovascular	health	 score,	used	 to	predict	 longevity	 and	healthy	
ageing,	were	similar	in	women	with	PCOS	and	age‐matched	controls.	
Of	 note,	 repeating	 all	 analyses	 with	 an	 age‐BMI	matched	 control	
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TA B L E  1  Characteristics	of	the	total	study	population
 PCOS (N = 200) Control (N = 200) P‐value
General/Obstetric	parameters
Age	(years) 50.5	(5.5) 51.0	(5.2) .35
BMI	(kg/m2) 28.4	(23.8‐32.9) 26.3	(23.7‐29.8) .02
Ethnicity	(Northern‐European) 170	(85.4%) 175	(87.5%) .50
Ever	smoker 78	(41.5%) 129	(64.8%) <.001
Age	at	menarche	(years) 13.7	(2.6) 12.8	(1.6) <.001
Postmenopausal 25	(16.0%) 81	(40.5%) <.001
OCP	use	(ever) 166	(83.4%) 182	(91%) .02
Amenorrhoea	(at	age	25) 14	(6.9%) 3	(1.5%) <.001
Oligomenorrhea	(at	age	25) 127	(62.9%) 22	(11.0%)
Regular	cycle	(at	age	25) 35	(17.3%) 131	(65.0%)
Education
Primary 2	(1.1%) 18	(9.0%) <.001* 
Lower/intermediate	or	lower	vocational 34	(18.0%) 77	(38.7%)
Intermediate	vocational	or	higher	general 70	(37.0%) 54	(27.1%)
Higher	vocational	or	university 79	(31.8%) 50	(25.1%)
Anthropometrics
Waist	(cm) 93.0	(84.5‐107.0) 85.9	(79.5‐94.6) <.001
Hip	(cm) 107.0	(99.5‐114.0) 106.5	(100.8‐112.6) .68
Waist/Hip	ratio 0.88	(0.83‐0.93) 0.81	(0.77‐0.86) <.001
Cardiometabolic	parameters
Systolic	BP	(mm	Hg) 130.0	(120.0‐140.0) 122	(112.0‐136.0) <.01
Diastolic	BP	(mm	Hg) 82.7	(11.3) 81.2	(11.3) .19
Hypertension 96	(48.2%) 53	(26.5%) <.001
Prevalent	CVD 3	(1.5%) 3	(1.5%) 1.00
Lipid	lowering	medication 13	(6.5%) 31	(15.6%) <.01
Total	cholesterol	(mmol/L) 5.3	(4.5‐6.0) 5.3	(4.8‐6.1) .44
HDL	cholesterol	(mmol/L) 1.5	(1.2‐1.8) 1.5	(1.2‐1.8) .68
LDL	cholesterol	(mmol/L) 3.3	(2.7‐4.0) 3.1	(2.6‐3.9) .42
Triglycerides	(mmol/L) 1.0	(0.8‐1.6) 1.1	(0.8‐1.5) .35
ASAT	(U/L) 22.0	(19.0‐25.0) 21.0	(18.0‐23.0) .09
ALAT	(U/L) 21.0	(16.0‐30.0) 20.0	(17.0‐25.0) .38
Gamma‐GT	(U/L) 20.0	(15.0‐29.0) 17.0	(13.0‐27.0) .02
NT‐pro‐BNP	(pmol/L) 7.0	(4.0‐13.0) 6.2	(4.1‐11.1) .40
Elevated	NT‐pro‐BNP	(>15	pmol/L) 27	(14.2%) 27	(18.8%) .26
Insulin	(pmol/L) 74.0	(47.0‐117.0) 72.0	(55.0‐105.0) .83
Glucose	(mmol/L) 5.3	(5.0‐5.7) 5.1	(4.8‐5.5) .02
HOMA‐IR 2.68	(1.54‐4.33) 2.43	(1.71‐3.69) .65
Diabetes 22	(11.1%) 13	(6.5%) .11
Metabolic	syndrome	(NCEP	definition) 45	(25.0%) 34	(17%) .06
Mean	carotid	cIMT	(um) 612.8	(93.6) 721.7	(118.4) <.001
Endocrine	parameters
FAI 1.9	(1.2‐2.9) 1.2	(0.8‐1.7) <.001
Testosterone	(nmol/L) 0.9	(0.6‐1.2) 0.8	(0.6‐1.1) .041
SHBG	(nmol/L) 48.5	(34.3‐70.7) 69.6	(46.7‐100.4) <.001
(Continues)
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population	yielded	similar	 results,	 suggesting	 the	outcomes	of	our	
study	were	not	driven	by	the	higher	BMI	in	women	with	PCOS.
Previous	studies	report	an	increase	of	CVD	risk	factors	in	women	
with	PCOS,	such	as	dyslipidemia,	insulin	resistance,	type	II	diabetes	
and	metabolic	syndrome.	This	 risk	 is	 increased	by	the	presence	of	
PCOS	per	se,	but	also	strongly	correlated	with	BMI	as	overweight	
and	obese	women	with	PCOS	are	most	at	risk.6,16,32,33	The	relatively	
low	BMI	in	our	PCOS	cohort	could	explain	the	seemingly	contradic‐
tory	results	in	the	prevalence	of	metabolic	syndrome	and	type	II	dia‐
betes.32,33	However,	it	also	seems	as	if	some	metabolic	disturbances	
associated	with	PCOS	are	detectable	at	any	age,	whilst	others	seem	
to	disappear	over	time.2,5,6,34	Evidence	suggests	that	of	the	lipid	dis‐
turbances	 associated	 with	 PCOS,	 increased	 triglyceride	 levels	 are	
the	 only	 lipid	 abnormality	 still	 detectable	 at	 older	 age.5,6,11,13	 The	
same	pattern	seems	to	apply	to	the	metabolic	syndrome,	which	has	
been	described	to	be	five	times	as	prevalent	in	young	women	with	
PCOS,	but	 to	 remain	only	 two	 times	as	prevalent	after	 the	age	of	
39.5,13	Another	possible	explanation	for	this	could	also	be	that	these	
women	were	already	diagnosed	early	on	during	their	reproductive	
years	 and	 were	 also	 informed	 about	 their	 long‐term	 health	 risks,	
which	they	might	have	adjusted	accordingly	 in	the	years	 following	
initial	diagnosis.
Conflicting	 results	 have	 been	 reported	 on	 cIMT	 and	 CVD	 in	
women	with	 PCOS.3,18,35	 Data	 on	 cIMT	 in	middle‐aged	 and	 older	
women	with	(features	of)	PCOS	are	scarce,	but	most	evidence	sug‐
gests	 a	 higher	 cIMT.3,11,36	 The	 lower	 cIMT	 in	 women	 with	 PCOS	
compared	to	age‐matched	controls	in	our	study	could	be	explained	
by	the	small	proportion	of	women	with	PCOS	who	were	postmeno‐
pausal	at	the	age	of	50.	The	menopausal	transition	is	associated	with	
an	increase	in	cIMT.31	The	fact	that	on	average,	women	with	PCOS	
enter	menopause	at	a	later	age	could	have	a	protective	effect	on	the	
development	of	atherosclerosis	and	risk	for	future	CVD.37,38	Indeed,	
most	 evidence	 points	 into	 the	 direction	 that	 the	 risk	 for	 CVD	 in	
women	with	PCOS	is	not	increased.	A	recent	large	Danish	study	in	
women	with	PCOS,	however,	demonstrated	higher	 incidence	rates	
of	CVD	already	an	early	age.14	In	this	study,	hypertension	and	dys‐
lipidemia	 were	 considered	 cardiovascular	 diseases	 and	 comprised	
the	majority	of	CVD	diagnosis.	 The	event	 rate	 for	 stroke	was	not	
increased	and	the	event	rate	for	ischaemic	heart	disease	in	women	
with	PCOS	was	slightly	increased	but	included	milder	forms	of	isch‐
aemic	heart	disease	(angina)	in	the	definition.14	Similarly,	in	the	cur‐
rent	study	we	detected	a	much	higher	prevalence	of	hypertension	
in	women	with	PCOS,	but	the	prevalence	of	cardiovascular	events	
was	similar	 to	 the	general	population	and	NT‐proBNP	as	a	marker	
for	heart	failure	was	not	 increased.	We	believe	most	evidence	still	
points	into	the	direction	that	long‐term	risk	for	CVD	events	(stroke,	
myocardial	infarction	and/or	coronary	heart	disease)	in	women	with	
PCOS	might	not	be	increased.6,11,13
How	is	it	possible	that	so	many	known	risk	factors	for	CVD	clus‐
ter	 in	women	with	PCOS	already	at	an	early	age,	yet	this	does	this	
not	seem	to	translate	into	an	increased	risk	for	cardiovascular	disease	
later	in	life?	It	might	be	that	there	is	an	early	worsening	in	risk	fac‐
tors	for	CVD	in	women	with	PCOS,	which	does	not	seem	to	progress	
much	over	the	years.5,6	Again	the	latter	might	be	due	to	the	fact	that	
women	are	aware	of	these	risk	factors	and	do	anticipate	accordingly	
to	them.	This	in	contrast	to	controls	who	seem	to	develop	metabolic	
abnormalities	gradually	over	time	and	apparently	end	at	a	similar	level	
as	women	with	PCOS.	Furthermore,	genetic	studies	have	provided	us	
 PCOS (N = 200) Control (N = 200) P‐value
Androstenedione	(nmol/L) 2.6	(1.9‐3.7) 3.0	(2.1‐4.0) .02
DHEA	(nmol/L) 9.8	(6.1‐14.3) 13.9	(9.5‐20.9) <.001
E2	(pmol/L) 150.5	(41.3‐383.3) 78.8	(18.4‐346.1) .03
Vitamin	D	deficiency 55	(36.9%) 78	(41.7%) .48
Note: Values	are	displayed	as	Means	(standard	deviation)	or	medians	(interquartile	range),	or	as	numbers	(percentage).	Differences	were	tested	with	
Student's	t	test	for	variables	with	a	normal	distribution,	and	Mann‐Whitney	U	test	was	used	for	variables	with	a	skewed	distribution.	Chi‐square	test	
or	Fisher's	exact	test	were	used	for	categorical	variables	Abbreviations:	Body	mass	index	(BMI),	oral	contraceptive	pill	(OCP),	blood	pressure	(BP),	
cardiovascular	disease	(CVD),	high‐density	lipoprotein	(HDL),	low‐density	protein	(LDL),	aspartate	aminotransferase	(ASAT	and,	alanine	aminotrans‐
ferase	(ALAT).
*use	of	Fisher’s	exact	test.	
TA B L E  1   (Continued)
F I G U R E  1  Ten‐year	risk	for	CVD	in	women	with	PCOS	and	
controls.	The	10‐year	risk	for	CVD	in	women	with	PCOS	and	age‐
matched	controls.	A	risk	of	<10%	was	marked	as	low	risk,	10%‐20%	
as	intermediate	and	>20%	as	high	risk.	Abbreviations:	polycystic	
ovary	syndrome	(PCOS),	not	significant	(NS)
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with	clues	suggesting	women	with	PCOS	might	be	able	to	compen‐
sate	 the	damage	caused	by	 this	unfavourable	 accumulation	of	 risk	
factors.	Genetic	variants	associated	with	late	menopause	and	asso‐
ciated	with	better	DNA	repair	and	maintenance	are	more	prevalent	
in	women	with	PCOS.	These	variants	are	correlated	with	long‐term	
health	and	longevity,	suggesting	a	potential	evolutionary	advantage	
for	women	with	PCOS.39,40	Indeed,	in	our	study	the	majority	of	mid‐
dle‐aged	women	with	PCOS	were	not	yet	postmenopausal	at	the	age	
of	50.	Finally,	hyperandrogenism	is	present	in	the	majority	of	women	
with	 PCOS	 and	 associated	 with	 cardiometabolic	 abnormalities	 at	
a	 younger	 age.	 In	 the	past,	 hyperandrogenism	was	 suggested	 as	 a	
main	driver	 for	 the	CVD	risk	 in	PCOS.2,34	The	effects	of	hyperan‐
drogenism	after	menopause	 are	 still	 heavily	 debated.	Whilst	 some	
consider	hyperandrogenism	to	be	a	risk	factor	for	CVD,	other	studies	
have	shown	that	hyperandrogenism	is	not	associated	with	a	higher	
risk	for	CVD	and	could	even	be	protective	against	CVD.9,11,13,41
All	 of	 these	 proposed	mechanisms	 could	 protect	 women	with	
PCOS	from	developing	CVD.	Despite	of	 their	unfavourable	profile	
at	 a	 younger	 age,	 long‐term	 cardiovascular	 health	 in	women	with	
PCOS	seems	to	be	similar	to	that	of	the	general	population.	Based	on	
the	selective	enrichment	with	better	DNA	repair	and	maintenance	
genes,	one	could	hypothesize	that	these	women	should	actually	be	
healthier	compared	to	the	general	population	provided	that	they	had	
received	proper	preventive	treatment	in	combination	with	a	healthy	
lifestyle	from	an	early	age	on.
This	is	one	of	the	largest	clinical	studies	assessing	the	cardiomet‐
abolic	profile	and	prevalence	of	CVD	in	women	diagnosed	with	PCOS	
around	the	age	of	50.	Besides	availability	of	several	subclinical	mea‐
sures	of	atherosclerosis,	detailed	information	on	study	subjects	made	
it	possible	to	comprehensively	address	the	cardiometabolic	profile	of	
these	women	and	to	estimate	their	risk	for	future	CVD.	The	limitations	
of	our	study	also	merit	consideration.	Our	data	set	is	quite	precise	and	
complete;	unfortunately,	we	were	still	sometimes	faced	with	missing	
data.	Although	this	was	only	the	case	for	a	small	proportion	of	the	data,	
this	may	have	led	to	an	underestimation	of	the	true	prevalence	of	for	
instance	 the	metabolic	 syndrome,	 as	we	were	not	 able	 to	assess	all	
parameters	in	all	patients.	In	addition,	although	our	study	population	
comprised	a	large	population	of	meticulously	phenotyped	women	with	
PCOS,	we	might	still	have	lacked	sufficient	power	to	detect	small	as‐
sociations.	Our	findings	therefore	still	need	to	be	validated	in	a	large	
cohort	of	women	with	PCOS	followed	up	until	old	age.
Studies	following	women	with	PCOS	until	very	old	age	will	even‐
tually	provide	definitive	answers	on	the	risk	for	CVD	and	the	involved	
mechanisms.	Therefore,	 cardiovascular	 assessment	 and	 follow‐up	of	
women	with	PCOS	are	still	necessary.	At	this	time,	however,	we	con‐
clude	that	although	some	metabolic	disturbances	were	present	in	our	
large	cohort	of	middle‐aged	women	with	PCOS,	we	found	no	evidence	
for	premature	atherosclerosis	or	an	increased	risk	for	future	CVD.	Only,	
time	will	tell	whether	this	will	indeed	translate	into	a	better	cardiovas‐
cular	health	in	women	with	PCOS	than	was	previously	anticipated.
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F I G U R E  2  Performance	of	women	
with	PCOS	and	controls	on	cardiovascular	
health	metrics.	Prevalence	(%)	of	poor,	
intermediate	and	ideal	cardiovascular	
heath	metrics	in	women	diagnosed	
with	PCOS	and	controls.	A	*denotes	
statistical	significance	of	<0.01,	**denotes	
a	statistical	significance	of	<0.001.	
Abbreviations:	BMI,	body	mass	index;	BP,	
blood	pressure;	PCOS,	polycystic	ovary	
syndrome
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